echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Professor Xia Ningshao's team published the final analysis results of the first domestic bivalent human papillomavirus vaccine Phase III clinical trial in The Lancet Infectious Diseases

    Professor Xia Ningshao's team published the final analysis results of the first domestic bivalent human papillomavirus vaccine Phase III clinical trial in The Lancet Infectious Diseases

    • Last Update: 2022-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cervical cancer is the second most common malignancy in women aged 15-44


    The research team carried out a multi-center, randomized, double-blind, controlled (hepatitis E vaccine Yikening ? ) Phase III clinical trial of Xinkening ? based on 5 sites across the country.


    The results of the final analysis of the 66-month follow-up of the Phase III clinical trial of Cincogene® showed that in the per-protocol set (PPS) population, the vaccine was effective against HPV type 16 and/or 18 infection-related lesion endpoints (CIN2+ and/or or VIN2+ and/or VaIN2+) protection was 100.


    Recently, the research results are titled "Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Human Papillomavirus (types 16 and 18) L1 Virus-like-particle Vaccine: end-of-study analysis of a phase 3 double-blind, The randomized controlled trial" paper is published online in The Lancet Infectious Diseases


    Paper link:National Research Center for Infectious Disease Diagnostic Reagents and Vaccine Engineering Technology)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.